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Molecular Epidemiology of Imipenem-Resistant Acinetobacter haemolyticus and
Acinetobacter baumannii Isolates Carrying Plasmid-Mediated OXA-40
from a Portuguese Hospital
Major outbreaks of multidrug-resistant Acinetobacter bau-
mannii associated with nosocomial infections have been in-
creasingly reported worldwide (1, 10, 12). The endemicity of an
OXA-24/40-producing A. baumannii clone associated with
mortality events in Portugal has been observed at numerous
hospitals within the Iberian Peninsula (5, 6, 10). Inversely,
Acinetobacter haemolyticus, isolated only occasionally from
clinical samples (9), usually presents susceptibility to different
antibiotics, including -lactams (13). The isolation of two car-
bapenem-resistant A. haemolyticus strains prompted us to as-
sess the relative contribution of clonal spread to the observed
high rate of carbapenem-resistant Acinetobacter spp. in a gen-
eral hospital in Porto, Portugal.
Between January 2001 and October 2004, 224 imipenem-
resistant Acinetobacter spp. were collected from several speci-
men sources and different hospital wards, where A. baumannii
was associated with nosocomial infections and colonizations
for several months (Table 1). Imipenem resistance significantly
increased from 2001 to 2002 and from 2002 to 2003. Macro-
restriction analysis of genomic DNA by pulsed-field gel elec-
trophoresis (5) and 16S rRNA gene sequencing, performed for
each clone and species representative, showed that, with the
exception of two clonally related A. haemolyticus isolates, the
remainder were A. baumannii isolates, distributed among three
different pulsotypes. Clonal dissemination of two major pulso-
types (A and B), widespread throughout the hospital, contrib-
uted to the observed A. baumannii imipenem resistance, which
has persisted since at least 2001 despite several elimination
attempts, including the use of polymyxin. Pulsotype B was
predominant from 2001 to 2002, after which clone A emerged
as the dominant type (Table 1). This clone was found to be
identical to the previously described Iberian OXA-24/40-pro-
ducing clone (5). Pulsotype C, with only two isolates, seemed
to represent a sporadic event within the observed prevalence of
clones A and B. Antimicrobial susceptibilities varied among
isolates according to clones (Table 2). A. haemolyticus isolates
presented resistance to all -lactams, with the exception of
cefepime, ceftazidime, and aztreonam. All Acinetobacter sp.
isolates were resistant to ciprofloxacin, whereas susceptibility
to aminoglycosides was variable. Only 11 isolates (including
the two A. haemolyticus isolates) showed a colistin MIC of 4
g/ml (2). However, when the recently updated CLSI suscep-
tible interpretative criterion of2 g/ml (3, 8) was applied, the
susceptibility rate dropped from 96.1% to 92.1%. Detection of
carbapenemase production, ulteriorly identified as an OXA-
24/40 enzyme, was performed as previously described (5) and
was positive only for clone A A. baumannii isolates and, for the
first time, A. haemolyticus isolates. Hybridization assays after
TABLE 1. Clinical data for imipenem-resistant Acinetobacter spp.a
Yr % Imipenem resistance(no. of isolates)d
Clone (no. of
isolates)b Ward(s) (no. of isolates)
Main specimen source(s)
(no. of isolates)c
2001 32 (47) A (14) ICU (8), ICU-P (2), ICU-S (1), NC (2), NK (1) Respiratory tract (12), urine (1),
NK (1)
B (33) ICU (6), ICU-P (14), CET (3), surgery 12B (3),
Med A, B, and D (3), OBS (2), neurology (1),
orthopedics (1)
Respiratory tract (13), urine (9),
pus (4), catheter (3), blood (3),
CSF (1)
2002 53 (31) A (6) ICU (4), Med B and C (2) Respiratory tract (5), urine (1)
B (22) Med B and D (7), ICU (5), ICU-P (6),
neurology (2), orthopedics (1), urology (1)
Respiratory tract (8), urine (10),
pus (1), blood (2), catheter (1)
A. haemolyticus (2) Endocrinology (1), Med B (1) Pus (1), urine (1)
2003 97 (104) A (53) ICU (25), CET (2), ICU-P (1), ICU-S (4), Med
D (2), OBS (1), orthopedics (1), NC (5),
surgery (9), urology (2), GIN (1)
Respiratory tract (27), pus (4), CSF
(4), blood (6), urine (6), ascitic
liquid (1), catheter (3), peritoneal
liquid (2)
B (9) Surgery 2 (2), PED (1), Med (5), ICU (1) Respiratory tract (3), urine (5),
blood (1)
C (2) Med D (1), ICU-P (1) Catheter (1), urine (1)
2004 98 (42) A (9) ICU (4), surgery (1), NC (1), Med (1), OBS (1),
oncology (1)
Respiratory tract (6), blood (1),
NK (2)
B (1) GIN (1) Urine (1)
a ICU, intensive care unit; Med, medical unit(s); ICU-P, polivalent ICU; ICU-S, postsurgical ICU; OBS, observation; NC, neurosurgery; PED, pediatrics; GIN,
gynecology; CET, cranium-encephalic traumatism; CSF, cerebrospinal fluid; NK, origin not known.
b Number of pulsotyped isolates (in 2003 and 2004, only representative isolates from the different hospital units were included). Clones are designated by capital
letters and refer to A. baumannii isolates.
c The respiratory tract includes sputum, bronchial secretions, and tracheal aspirate.
d P was 0.01 for the difference between the two values (after Bonferroni’s adjustment) for 2001 and 2002, and P was 0.001 for the difference between the two
values for 2002 and 2003. No significant differences were observed between 2003 and 2004 (P  0.73)
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both S1 nuclease digestion and I-CeuI digestion, performed as
previously described (7), revealed that although some clone A
A. baumannii isolates showed a chromosome-positive signal
(ca. 150 kb) for the blaOXA-24/40 probe, most also presented a
positive hybridization in plasmidic bands of ca. 180 kb and ca.
30 kb. Similar hybridization signals were observed in the A.
haemolyticus isolates. Further studies on plasmid characteriza-
tion, assessing the homology among different plasmids, are
ongoing.
We describe, for the first time, the presence of an OXA-
24/40 enzyme in an A. haemolyticus clinical isolate. Although
the spread of OXA-24/40, both in the Iberian Peninsula and in
France, has been correlated with the progressive dissemination
of a single A. baumannii clone, the observation of this enzyme
in a different, previously unreported, genomic species, A. hae-
molyticus, poses new questions on OXA-24/40 dissemination.
It now seems reasonable to suspect a horizontal dissemination
of the blaOXA-40 gene between different species, an ability
supported by the observation of this enzyme, previously de-
scribed as chromosomally encoded (7), in a plasmid. Notwith-
standing, the dissemination of “successful” clones may possibly
contribute to the high rates and persistence of imipenem-re-
sistant A. baumannii isolates (4).
We are grateful to Nuno Monteiro for helpful discussions and crit-
ical review of the manuscript.
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TABLE 2. In vitro susceptibilities of imipenem-resistant Acinetobacter sp. clinical isolates
Species Clone Carbapenemaseproduction
MIC range (g/ml)a
IPM MEM AMX AMC CAZ FEP FOX TIC TIM PIP TZP ATM CST
A. baumannii A blaOXA-40 32 32 256 256 256 32 256 256 256 256 256 8–256 1–16
B Negb 32 2–8 64–256 64–256 4–8 8–24 256 256 256 256 256 16–256 1–16
C Neg 32 4 128 256 4 2 256 256 256 64 64 8 2–4
A. haemolyticus blaOXA-40 32 32 256 256 4 4 32 256 256 256 256 4 4
a IPM, imipenem; MEM, meropenem; AMX, amoxicillin; AMC, amoxicillin-clavulanic acid; CAZ, ceftazidime; FEP, cefepime; FOX, cefoxitin; TIC, ticarcillin; TIM,
ticarcillin-clavulanic acid; PIP, piperacillin; TZP, piperacillin-tazobactam; ATM, aztreonam; CST, colistin. The MICs of -lactams were determined by the Etest method
and those of colistin by the agar dilution method (11).
b Neg, absence of carbapenemase production.
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